Could a Low-Dose opioid blocker ease diabetic nerve pain without the risks?

NCT ID NCT04678895

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether low-dose naltrexone (LDN) can safely reduce pain from diabetic neuropathy, a common complication of diabetes. Thirty-five adults who have not found relief from standard treatments will receive LDN and a placebo in random order. The goal is to see if LDN offers a non-opioid alternative for managing this chronic pain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
low-dose naltrexone (LDN)
What this could lead to
If it works, this could offer a safe, non-opioid pain relief option for people with painful diabetic neuropathy.
What could go wrong
This is a small, early-phase trial with only 35 participants. It may not show a clear benefit, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAINFUL DIABETIC NEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dartmouth-Hitchcock Medical Center

    RECRUITING

    Lebanon, New Hampshire, 03766, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.